Use of osteopontin for the treatment and/or prevention of neurologic diseases

Patent Number: 7,217,687

Osteopontin, is a protein also called cytokine Eta-1, which contains Arg-Gly-Asp-Ser (RGDS) cell-binding sequences. Osteopontin is associated with cancer metastasis, as well as inflammatory immune cell migration, it interacts with alpha(v)beta1, alpha(v)beta3 and alpha(v)beta5 integrins and CD44 receptors.

The current patent covers the use of osteopontin and various derivatives for treatment of neurological diseases. Specifically, the inventors discovered remyelinating and endogenous stem cell activating activities of osteopontin. Concentrations and various delivery methods are also covered.

Examples in the patent include the administration of osteopontin to induce remyelination in vivo, as well as stimulating of nerve regeneration after sciatic injury.

View this patent on the USPTO website.